Press Releases August 26, 2026 09:15 AM

Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Inspire Medical Systems to Present at Wells Fargo 21st Annual Healthcare Conference

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
INSP

Inspire Medical Systems, Inc., a developer of innovative therapies for obstructive sleep apnea, announced its upcoming presentation at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The event will feature management discussing company developments and will be accessible via a live webcast.

Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
INSP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Inspire Medical Systems focuses on minimally invasive solutions for obstructive sleep apnea patients.
  • The company’s proprietary Inspire therapy is FDA and EU-approved neurostimulation technology for moderate to severe obstructive sleep apnea.
  • Presentation at a major healthcare conference highlights ongoing investor engagement and communication.

MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.

Inspire is scheduled to present at 1:30 p.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Louisa Smith
Principal, Gilmartin Group
[email protected]


Risks

  • Market adoption and reimbursement for new medical therapies could impact future revenue.
  • Regulatory changes or challenges with medical device approvals may affect product commercialization.
  • Competition in the medical technology and sleep apnea treatment sectors could affect market share.

More from Press Releases

Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026